East-West Symposium on nasopharyngeal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 3, 2007, Pages 703-708

  Liu, Fei Fei ^a,b,c   Frappier, Lori ^d   Kim, John ^a,b   O'Sullivan, Brian ^a,b   Hui, Angela ^b,c   Bastianutto, Carlo ^b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy; Clinical trials; Epidemiology; Epstein Barr Virus; Expression arrays; Nasopharyngeal cancer; Radiation therapy

Indexed keywords

BIOLOGICAL ORGANS; EPIDEMIOLOGY; PATHOLOGY; RADIOTHERAPY; VIRUSES;

CLINICAL TRIALS; EPSTEIN-BARR VIRUS; EXPRESSION ARRAYS; NASOPHARYNGEAL CANCER;

TUMORS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; AZACITIDINE; CARBOPLATIN; CETUXIMAB; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SIMVASTATIN;

ARTICLE; CANADA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CORRELATION ANALYSIS; DOWN REGULATION; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR DYNAMICS; NASOPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; ONTARIO;

EID: 33846826896     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.09.014     Document Type: Article

References (48)

1. Yu M.C., and Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 421-429
2. Raab-Traub N., and Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47 (1986) 883-889
3. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12 (2002) 431-441
4. Lee A.W., Sze W.M., Au J.S., et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 61 (2005) 1107-1116
5. Lo K.W., To K.F., and Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 5 (2004) 423-428
6. Busson P., Keryer C., Ooka T., and Corbex M. EBV-associated nasopharyngeal carcinomas: From epidemiology to virus-targeting strategies. Trends Microbiol 12 (2004) 356-360
7. Friborg J., Wohlfahrt J., Koch A., et al. Cancer susceptibility in nasopharyngeal carcinoma families-a population-based cohort study. Cancer Res 65 (2005) 8567-8572
8. Zeng M.S., Li D.J., Liu Q.L., et al. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 79 (2005) 15323-15330
9. Baer R., Bankier A.T., Biggin M.D., et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310 (1984) 207-211
10. Wu L., Borza C.M., and Hutt-Fletcher L.M. Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells. J Virol 79 (2005) 10923-10930
11. Kapoor P., Lavoie B.D., and Frappier L. EBP2 plays a key role in Epstein-Barr virus mitotic segregation and is regulated by aurora family kinases. Mol Cell Biol 25 (2005) 4934-4945
12. Saridakis V., Sheng Y., Sarkari F., et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18 (2005) 25-36
13. Moody C.A., Scott R.S., Amirghahari N., et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 79 (2005) 5499-5506
14. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 (2004) 757-768
15. Yajima M., Kanda T., and Takada K. Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol 79 (2005) 4298-4307
16. Tierney R.J., Edwards R.H., Sitki-Green D., et al. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: Comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis 193 (2006) 287-297
17. Cheung S.T., Huang D.P., Hui A.B., et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83 (1999) 121-126
18. Amon W. Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15 (2005) 149-156
19. Pioche-Durieu C., Keryer C., Souquere S., et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol 79 (2005) 13326-13337
20. Seto E., Yang L., Middeldorp J., et al. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 76 (2005) 82-88
21. Hong G.K., Kumar P., Wang L., et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 79 (2005) 13984-13992
22. Shi W., Bastianutto C., Li A., et al. Therapeutic opportunities for nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 119 (2006) 2467-2475
23. Kwong J., Lo K.W., To K.F., et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8 (2002) 131-137
24. Chow L.S., Lam C.W., Chan S.Y., et al. Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene 12 (2006) 310-316
25. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
26. Zhang X., Uthaisang W., Hu L., Ernberg I.T., and Fadeel B. Epstein-Barr virus-encoded latent membrane protein 1 promotes stress-induced apoptosis upstream of caspase-2-dependent mitochondrial perturbation. Int J Cancer 113 (2005) 397-405
27. Yip K.W., Mocanu J.D., Au P.Y., et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11 (2005) 8131-8144
28. Cohen J.I. HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. Br J Cancer 92 (2005) 1593-1598
29. Khanna R., Moss D., and Gandhi M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol 2 (2005) 138-149
30. Jurgens L.A., Khanna R., Weber J., and Orentas R.J. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol 26 (2006) 22-2
31. Gottschalk S., Heslop H.E., and Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 46 (2005) 1-10
32. Gottschalk S., Heslop H.E., and Roon C.M. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 84 (2002) 175-201
33. Israel B.F., Gulley M., Elmore S., et al. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 4 (2005) 2037-2044
34. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 43 (2005) 3066-3073
35. Chan K.C., Chan A.T., Leung S.F., et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 51 (2005) 2192-2195
36. Chan K.C., Zhang J., Chan A.T., et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63 (2003) 2028-2032
37. Lo Y.M., Chan L.Y., Lo K.W., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59 (1999) 1188-1191
38. Lo Y.M., Leung S.F., Chan L.Y., et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 60 (2000) 2351-2355
39. Lin J.C., Wang W.Y., Chen K.Y., et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350 (2004) 2461-2470
40. Karray H., Ayadi W., Fki L., et al. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 75 (2005) 593-602
41. Stevens S.J., Verkuijlen S.A., Hariwiyanto B., et al. Noninvasive diagnosis of nasopharyngeal carcinoma: Nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 119 (2006) 608-614
42. Lee A.W., Lau W.H., Tung S.Y., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (2005) 6966-6975
43. Baujat B., Audry H., Bourhis J., et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (2006) 47-56
44. Chan A.T., Hsu M.M., Goh B.C., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23 (2005) 3568-3576
45. Kelly W.K., and Marks P.A. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2 (2005) 150-157
46. Ma B.B., and Chan A.T. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 6 (2006) 383-394
47. Straathof K.C., Bollard C.M., Popat U., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105 (2005) 1898-1904
48. Kwong D.L., Sham J.S., Leung L.H., et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64 (2006) 374-381